UM
(Note: the search results are based on claimed items)

Browse/Search Results:  1-4 of 4 Help

Filters        
Selected(0)Clear Items/Page:    Sort:
Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2018,Volume: 18,Issue: 4,Page: 550-555
Authors:  Tang Z.-H.;  Su M.-X.;  Guo X.;  Jiang X.-M.;  Jia L.;  Chen X.;  Lu J.-J.
Favorite  |  View/Download:0/0  |  Submit date:2018/12/28
AZD9291  EGFR  IRE1α  Lune cancer  NSCLC  Osimertinib  
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies Journal article
CANCER LETTERS, 2018,Volume: 420,Page: 242-246
Authors:  Tang, Zheng-Hai;  Lu, Jin-Jian
Favorite  |  View/Download:2/0  |  Submit date:2018/10/30
Osimertinib  AZD9291  EGFR TKI  Resistant mechanisms  Therapeutic strategies  
Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells Journal article
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017,Volume: 321,Page: 18-26
Authors:  Tang, Zheng-Hai;  Cao, Wen-Xiang;  Su, Min-Xia;  Chen, Xiuping;  Lu, Jin-Jian
Favorite  |  View/Download:2/0  |  Submit date:2018/10/30
Osimertinib  AZD9291  Autophagy  Apoptosis  ROS  
Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line Journal article
Oncotarget, 2016,Volume: 7,Issue: 49,Page: 81598-81610
Authors:  Tang Z.-H.;  Jiang X.-M.;  Guo X.;  Fong C.M.V.;  Chen X.;  Lu J.-J.
Favorite  |  View/Download:0/0  |  Submit date:2018/12/28
AZD9291  EGFR  Navitoclax  NSCLC  Osimertinib